Furthermore, phosphorylated nuclear iASPP (Inhibitor of apoptosis-stimulating protein of p53) has been reported to correlate with MDM2 overexpression in wild-type p53 melanoma cells [37], highlighting the need to co-target, at least, MDM2 and iASPP to optimally reactivate p53. Here, TP53 is linked to melanoma.